Low serum levels of 25-hydroxyvitamin D may be associated with elevated blood glucose levels, a major risk factor for type 2 diabetes.
Rates of diabetes screening are high, with hemoglobin A1c (HbA1c) used less but more likely to result in clinical diagnosis.
The short-term use of intravenous unacylated ghrelin infusion does not appear to have an effect on either substrate metabolism or insulin sensitivity in men with type 2 diabetes.
Most patients with type 1 diabetes will experience clinically meaningful differences in glucose level results when comparing laboratory-measured HbA1c levels with HbA1c levels derived from a glucose management indicator.
Screening for diabetic retinopathy in primary care settings has the potential to reach most U.S. adults with diabetes.
The use higher insulin doses in patients with type 1 diabetes can alter several cardiovascular risk factors without increasing cardiovascular outcomes.
The AACE and ACE published an annual update to their joint type 2 diabetes management algorithm.
Tandem Diabetes Care announced that the Food and Drug Administration (FDA) has authorized the t:slim X2 insulin pump with interoperable technology, the first of the Alternate Controller Enabled Infusion Pumps.
Roux-en-Y gastric bypass surgery is associated with remission from type 2 diabetes and substantially reduced the risk for microvascular complications.
Boehringer Ingelheim and Lilly announced that the CAROLINA trial met its primary endpoint, demonstrating no increased cardiovascular (CV) risk with linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, when compared with glimepiride, a sulfonylurea, in patients with type 2 diabetes and CV risk.